Jesse Shefferman's most recent trade in Protara Therapeutics Inc was a trade of 10,200 Common Stock done . Disclosure was reported to the exchange on June 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jun 2025 | 10,200 | 963,253 (16%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jun 2025 | 3,400 | 973,453 (16%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jun 2025 | 3,367 | 959,886 (16%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jun 2025 | 1,700 | 976,853 (16%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Jun 2025 | 300,000 | 659,886 (11%) | 5% | 0 | Common Stock | |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 387,000 | 387,000 | - | - | Stock Option (Right to Buy) | |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 65,000 | 994,022 (17%) | 1% | 0 | Common Stock | |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. | 21 Jan 2025 | 15,469 | 913,553 (15%) | 0% | 4.8 | 73,632 | Common Stock |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.14 per share. | 03 Jan 2025 | 6,479 | 929,022 (15%) | 0% | 6.1 | 39,781 | Common Stock |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Aug 2024 | 5,263 | 938,801 (16%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Aug 2024 | 3,300 | 935,501 (16%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Shefferman Jesse | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 357,000 | 357,000 | - | - | Stock Option (Right to Buy) | |
| Protara Therapeutics Inc | Shefferman Jesse | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 59,000 | 951,867 (16%) | 1% | 0 | Common Stock | |
| Protara Therapeutics Inc | Shefferman Jesse | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.91 per share. | 19 Jan 2024 | 7,803 | 944,064 (16%) | 0% | 1.9 | 14,904 | Common Stock |
| Protara Therapeutics Inc | Shefferman Jesse | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.39 per share. | 10 Jan 2024 | 5,746 | 892,867 (15%) | 0% | 2.4 | 13,733 | Common Stock |
| Protara Therapeutics Inc | Shefferman Jesse | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 03 Jan 2024 | 5,840 | 898,613 (15%) | 0% | 2.2 | 12,673 | Common Stock |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 307,500 | 307,500 | - | - | Stock Option (Right to Buy) | |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 51,300 | 918,282 (15%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.00 per share. | 10 Jan 2023 | 5,855 | 866,982 (14%) | 0% | 3 | 17,565 | Common Stock |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.80 per share. | 03 Jan 2023 | 6,604 | 872,837 (14%) | 0% | 2.8 | 18,491 | Common Stock |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 3.84 per share. | 11 Aug 2022 | 9,065 | 879,441 (15%) | 0% | 3.8 | 34,810 | Common Stock |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.27 per share. | 10 Jan 2022 | 5,080 | 872,425 (14%) | 0% | 6.3 | 31,852 | Common Stock |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 253,500 | 253,500 | - | - | Stock Option (Right to Buy) | |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 42,300 | 877,505 (15%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 202,000 | 202,000 | - | - | Stock Option (Right to Buy) | |
| Protara Therapeutics Inc | Jesse Shefferman | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.16 per share. | 11 Jan 2021 | 5,069 | 835,205 (14%) | 0% | 21.2 | 107,260 | Common Stock |